Hi Elizabeth, glad to hear that your Neuro is looking at Tovaxin for you. I am personally very excited about this new treatment option, and wish you all the best with getting into the trial.

Hi Lauren, and welcome aboard.

I think you are going to like NeuroTalk, and I am sure you will find it very refreshing to meet such a fine group of astute and well informed members to interact with.

When I read your first two identical postings on this forum, my first thought was that you were a sales rep for Biogen. IMO, most of your posts read like some sort of over-the-top advertising campaign, with hugely broad-sweeping statements about a yet very controversial & unproven drug (in the l/t). Given that you too are a PwMS, I can see you are just very excited about having another treatment option available to you.

Please know that I wish you continued health and success from using Tysabri . . . however, I am concerned about some of your statements, assumptions, and a seemingly biased viewpoint about this drug. While I agree that none of us should have to defend our chosen treatment, we may very well be challenged on our ‘perception’ of the “facts”.

If I were in your shoes, this would have had ME questioning whether Tysabri might have actually caused the relapse, since this "severe relapse" occurred so shortly after the infusion.

Of course that is HIGHLY unlikely, but it just goes to shows that we can not jump to conclusions when we try new meds, especially after only one treatment.

Didn’t you only have the one infusion in 2005, then experienced another attack within a few months of it? (I understand that you have recently had another infusion, about a week ago too).

If this is your only experiences to date with this drug, how have you have already come to the conclusion that this is the “only MS therapy that has stopped my attacks”?

How do you know that Tysabri is going to work for stopping YOUR relapses with so little history to base your opinion on?

There are many choices of therapy available to us, not just those that are currently endorsed by the pharma companies and/or supported by the NMSS. Your comment, that you 'support people’s right to choose', does not seem represented by such points (above).

This is getting to be very OLD news now, but thank you for sharing your tape.

What does that sentence mean; "68% superior efficacy”. 68 percent superior to what?

Are you aware that the PRIMARY, and most important measure for a drugs effectiveness is it's influence on disease PROGRESSION? Tysabri did NOT fair significantly better in this regard, with the following reported/comparative results:

"In the AFFIRM monotherapy trial, 29% of placebo patients but 17% of Tysabri patients progressed in a two year period (based on a statistical model), a difference of 12%.

In the PRISMS Rebif trial, 37% of placebo patients but 26% of Rebif (44mg) progressed in a two year period, a difference of 11%.

In the phase III Avonex trial, 35% of placebo patients but 22% of Avonex patients progressed in a two year period, a difference of 13%."

QUOTE: XO++, Mark

Relapse rates, for which you have quoted the efficacy rate of 68% is simply a SECONDARY measure of a drug’s effectiveness. Although I agree it’s kinda’ nice if we happen to be one of the lucky ones to experience less relapses due to a drug, if it doesn’t significantly impact disability accumulation, quite frankly I’m not getting all that excited.

The “reduced relapses” stats that are presented to us, i.e. the 68% that you are advertising for Tysabri, are RELATIVE TO PLACEBO, not absolute. This is NOT very a forthright representation of how effective they are, IMHO. The same holds true for the “enhancing lesions” reduction stat, and a correlation between the reduced # of enhanced lesions' effect on disease progression.

The link that Sally provided for your reference is extremely relevant to the efficacy of these drugs, and may influence our decisions. Therefore, I encourage you to “point out the falsehoods for everyone to see” by providing specific details about where there is misinformation being presented.

Again, welcome to the board, Lauren. Hope you enjoy it here.

Cherie